Skip to main content
Clinical Trials/JPRN-jRCT1040220052
JPRN-jRCT1040220052Recruiting未知

Observational study to establish evaluation method for vascular abnormalities using deep learning

Michio Ozeki0 sites20 target enrollmentStarted: August 11, 2022Last updated:

Trial Snapshot

Phase
未知
Status
Recruiting
Sponsor
Enrollment
20

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
ot applicable to ot applicable (—)
Sex
All

Inclusion Criteria

  • 1, A multicenter phase III investigator-initiated clinical trial (NPC-12T-LM study) conducted from 2017 to 2019 to investigate the efficacy and safety of NPC-12T (sirolimus) for intractable lymphatic disease, Multi-center, open-label, uncontrolled study to investigate the safety and efficacy of sirolimus for refractory vascular and lymphatic diseases (SRL-CVA-01 study, jRCTs031180290) started in 2017, and Conducted from 2020 to 2022, a multicenter phase III investigator-initiated clinical trial (NPC -12T-CVA)
  • 2) Patients with evaluable MRI images
  • 3) Patients who agreed to participate in this study

Exclusion Criteria

  • 1) Patients with other than obvious vascular abnormalities
  • 2) Patients with clearly different lesions and image artifacts such as bleeding and inflammation that are difficult to evaluate
  • 3) Other patients who are judged to be inappropriate by the principal investigator or co-investigator

Investigators

Sponsor
Michio Ozeki

Similar Trials